Given our results showing the BM stroma mediated activation of JNK and PI3K signalling pathways in MPN cells (Fig 2), we tested combinations of Vorinostat and Ruxolitinib with pharmacological inhibitors of such pathways. This evidence concerns the gene MAPK8 and myeloproliferative neoplasm.